Stockholders' Deficit - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Jul. 29, 2026 |
Dec. 31, 2025 |
|
| Stockholders' Deficit | |||||
| Proceeds from issuance of common shares | $ 3,004 | $ 17,304 | |||
| Principal amount | $ 63,848 | $ 66,644 | |||
| Number of warrants, Granted | 9,700,000 | ||||
| Weighted Average Exercise Price -Granted | $ 0.21 | ||||
| Pre Modification | |||||
| Stockholders' Deficit | |||||
| Incremental stock-based compensation for stock options modification | $ 900 | ||||
| July Convertible Notes | |||||
| Stockholders' Deficit | |||||
| Principal amount | $ 4,900 | ||||
| July convertible note | |||||
| Stockholders' Deficit | |||||
| Weighted Average Exercise Price -Granted | $ 0.205 | ||||
| Fair value of warrants | $ 800 | ||||
| Common Stock | |||||
| Stockholders' Deficit | |||||
| Number of shares issued during the period | 22,385,000 | 12,926,000 | 78,523,000 | ||
| Maximum | July convertible note | |||||
| Stockholders' Deficit | |||||
| Number of warrants, Granted | 9,700,000 | ||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Face (par) amount of debt instrument at time of issuance. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition An excess of the fair value of the modified award over the fair value of the award immediately before the modification. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|